Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...
TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in ...
Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in adults. As a ...
Please provide your email address to receive an email when new articles are posted on . TNKase is the first stroke treatment approved by the FDA in almost 30 years, the manufacturer said. It is ...
THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic ...
The 5-second intravenous bolus offers faster, simpler administration than Activase. (HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or ...
From breaking news to special features, we're on it! Join the NonStop Local Chord group and always be in the know. THURSDAY, March 6, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results